Drug intelligence / Profile preview

GSK4001785A

Development stage: Unknown
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**GSK4001785A** is an investigational vaccine candidate developed by GSK targeting *Shigella* infection. It is part of the altSonflex1-2-3 GMMA (Generalized Modules for Membrane Antigens) vaccine platform, designed to elicit bactericidal antibodies effective against a panel of drug-resistant *Shigella* clinical isolates. The vaccine aims to provide protection against shigellosis, a major cause of diarrheal disease, particularly in vulnerable populations in low- and middle-income countries, through intramuscular administration in early-phase clinical trials.

Beyond the preview

Go deeper on GSK4001785A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK4001785A.

Explore the full profile